Paige has launched OmniScreen, an AI-driven biomarker module capable of evaluating over 505 genes and detecting 1,228 molecular biomarkers from routine H&E-stained digital pathology slides.
Built on Paige’s second-generation foundation model, trained on three million slides, this module represents a leap forward in the accuracy, speed and cost-effectiveness of cancer diagnosis and treatment selection.
Unlike traditional methods that require separate models for each biomarker or cancer type, Paige OmniScreen employs a single AI module capable of predicting a broad spectrum of clinically relevant molecular biomarkers across multiple cancer types. By replicating a targeted biomarker gene panel of 505 genes, it can simultaneously predict 1,228 biomarkers in the 15 most common cancers, including actionable targets such as BRAF, EGFR, KRAS, MET and FGFR3. Additionally, it links phenotypes with genetic patterns, simplifying the diagnosis of conditions defined by specific genetic markers. This capability unlocks deeper, more comprehensive insights into cancer biology and paves the way for new treatment strategies.
This technology accelerates drug development by identifying new potential indications through pan-tumor screening for targeted genetic mutations and enhances patient selection for clinical trials. By pre-screening patients before costly molecular tests, Paige OmniScreen offers substantial cost savings for clinical trials and laboratories, ultimately making personalized therapies more accessible and affordable for a broader range of patients.
“The development of our digital biomarker panel represents a significant advancement in personalized medicine, addressing many of the challenges associated with traditional molecular biomarker tests,” said Razik Yousfi, CTO and CEO of Paige. “Our innovative approach minimizes the need for extensive tissue samples, making it particularly useful in cases where biopsy tissue is limited. This first of its kind AI-module offers detailed insights into cancer biology and potential treatment avenues by predicting the activity of canonical signaling pathways, DNA repair mechanisms, and genomic instability measures.”
“Such comprehensive analysis is crucial in identifying genetic alterations and holds immense potential for guiding therapy selection, improving treatment efficacy, and accelerating patient screening for clinical trials,” stated Dr. David Klimstra, Founding Medical Officer of Paige. “By enabling the quick identification of cases that warrant further genomic testing, we’re enhancing clinical decision-making, reducing turnaround times, and lowering testing costs — all while ensuring the highest standards of patient care. This is a game-changer in the pursuit of better cancer treatments and improved patient outcomes.”
April 01, 2026 
